SalaryGuide
SalariesCompaniesJobs
AboutPricingBlog
For Employers

Marketing jobs

5 marketing jobs

Sarepta Therapeutics logo
14 hrs ago

Manager, Marketing Programs and Engagement

Sarepta Therapeutics

Cambridge, MA (Hybrid)Full time$116K/yr – $145K/yr
Sarepta Therapeutics logo
14 hrs ago

Director, Digital Marketing & Strategy

Sarepta Therapeutics

Cambridge, MA (Hybrid)Full time$186K/yr – $232K/yr
Sarepta Therapeutics logo
19 hrs ago

Manager, Marketing Programs and Engagement

Sarepta Therapeutics

Cambridge, MA (Hybrid)Full time$116K/yr – $145K/yr
Sarepta Therapeutics logo
19 hrs ago

Director, Digital Marketing & Strategy

Sarepta Therapeutics

Cambridge, MA (Hybrid)Full time$186K/yr – $232K/yr
Sarepta Therapeutics logo
7 months ago

Assoc. Director, DMD Patient Marketing

Sarepta Therapeutics

Cambridge, MA (Hybrid)Full time$161K/yr – $201K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Sarepta Therapeutics logo

Manager, Marketing Programs and Engagement

Sarepta Therapeutics

Cambridge, MA (Hybrid)

$116K/yr - $145K/yrIn-houseFull-timeManager5+ years exp.
14 hrs ago
Sarepta Therapeutics logo

Director, Digital Marketing & Strategy

Sarepta Therapeutics

Cambridge, MA (Hybrid)

$186K/yr - $232K/yrIn-houseFull-timeDirector/executive10+ years exp.
14 hrs ago
Sarepta Therapeutics logo

Manager, Marketing Programs and Engagement

Sarepta Therapeutics

Cambridge, MA (Hybrid)

$116K/yr - $145K/yrIn-houseFull-timeManager5+ years exp.
19 hrs ago
Sarepta Therapeutics logo

Director, Digital Marketing & Strategy

Sarepta Therapeutics

Cambridge, MA (Hybrid)

$186K/yr - $232K/yrIn-houseFull-timeDirector/executive
19 hrs ago
Sarepta Therapeutics logo

Assoc. Director, DMD Patient Marketing

Sarepta Therapeutics

Cambridge, MA (Hybrid)

$161K/yr - $201K/yrIn-houseFull-timeManager10+ years exp.
7 months ago
Sarepta Therapeutics logo
Sarepta Therapeutics

Manager, Marketing Programs and Engagement

Cambridge, MA (Hybrid)

$116K/yr – $145K/yrManager5+ years expFull time

Posted 14 hrs ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own end-to-end promotional and educational programs, translating brand strategy into executable experiences across HCP and patient education, with cross-functional governance and measurement.

  • Lead end-to-end program planning and execution across marketing, Medical Affairs, and Patient Affairs
  • Drive cross-functional collaboration with agencies, KOLs, and internal partners to deliver measurable outcomes

Job Description

Responsibilities

  • Support end-to-end planning and execution of promotional HCP programs, and educational patient programs.
  • Translate brand strategy and audience insights into actionable program plans, experiences, and tactics.
  • Manage program development from concept through execution, including timelines, budgets, agencies, vendors, content, logistics, approvals, and measurement.
  • Support development and execution of HCP educational programs including speaker programs, peer-to-peer education, webinars, regional programs, and other professional engagement initiatives.
  • Support development of and execution of patient and caregiver education programs in partnership with Patient Education Liaison team, Patient Affairs, and other cross-functional stakeholders.
  • Work with internal and external partners to develop all logistical materials related to programs.
  • Support operational planning and execution of commercial symposia, product theaters, speaker programs, booth development, and other congress-related engagements.
  • Partner with Marketing and cross-functional stakeholders to identify strategic opportunities for congress engagement.
  • Coordinate faculty identification, agency partners, content development, speaker preparation, logistics, and onsite execution.
  • Partner with Opinion Leader Programming, Medical Affairs, and Legal/Regulatory/Compliance to ensure appropriate review and approval of program content.

Requirements

  • Bachelor's degree required
  • 5+ years of experience in pharmaceutical/biotech marketing, preferably within rare disease, specialty pharma, or another complex therapeutic area.
  • Experience executing HCP education, patient education, speaker programs, symposia, congress programs, or similar commercial initiatives.
  • Strong project/program management skills with demonstrated ability to manage multiple complex initiatives simultaneously.
  • Experience working with external agencies, vendors, KOLs, and healthcare professionals.
  • Understanding of MLR processes.
  • Demonstrated ability to work effectively across Marketing, Medical Affairs, Regulatory, Legal, Sales, Patient Affairs, and other functions.
  • Strong communication, organizational, and problem-solving skills.
  • Ability to operate independently in a fast-paced environment and drive execution without direct authority.

Benefits

  • Physical and Emotional Wellness
  • Financial Wellness
  • Support for Caregivers
  • For a full list of our comprehensive benefits, see our website: https://www.sarepta.com/join-us
Sarepta Therapeutics logo

Sarepta Therapeutics

4.4 Glassdoor

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. For information on our Community Guidelines, please visit sarepta.com/community-guidelines.We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://www.sarepta.com/recruiting-fraud

Founded in 1980
Cambridge, Massachusetts, USA
1.2K employees (43 in marketing)
www.sarepta.com
89% recommend to a friend
94% CEO approval

Salaries

Posted range

$116K/yr – $145K/yr

Taken straight from the job posting.

See all Sarepta Therapeutics salaries

Marketing Team

Marketing Team Size
32 (3% of company)
Median Career Experience
19.5 years
Median Tenure
4.8 years
Marketing Roles Posted (Last 30 Days)
2

People

Marketing Leadership

Michael Maurer
Michael Maurer
Vice President, Head of Commercial Strategy and Marketing at Sarepta Therapeutics
At the company for 6 years 1 month
Jeff Bagull
Jeff Bagull
Head of Payer Marketing
At the company for 5 years
Brian Tartufo
Brian Tartufo
Director HCP PMO Marketing
At the company for 4 years 6 months
Andrew Barrett
Andrew Barrett
Associate Director, Gene Therapy Marketing
At the company for 3 years 10 months

Funding

Total Funding
$2.9B
Last Raise
$291.4M
Post IPO Debt, 3 months ago

Funding History

  • Dec 2025
    Post IPO Debt • $291.4M
  • Aug 2025
    Post IPO Debt • $602M
  • Aug 2025
    Post IPO Equity

Traffic Signals

Monthly Visitors
58.1K
Traffic Source Mix
Search
55%
Direct
35.6%
Referral
6.4%
Social
1.9%
Paid
0.9%

Headcount Trend

Current headcount: ~1.2K

Recent News

Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction
Nov 25, 2025 • Fierce Pharma
FDA’s stronger warning on Sarepta gene therapy raises new questions about heart risk
Nov 18, 2025 • statnews.com
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys
Nov 17, 2025 • BioSpace
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
Nov 17, 2025 • Yahoo Finance
Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year?
Nov 15, 2025 • Yahoo Finance
FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths
Nov 14, 2025 • Fierce Pharma
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Nov 14, 2025 • Sarepta Therapeutics
How the Story Around Sarepta Therapeutics Is Shifting Amid New Analyst Reactions and Clinical Updates
Nov 5, 2025 • Yahoo Finance
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say
Nov 4, 2025 • Yahoo Finance
Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial
Nov 4, 2025 • Clinical Trials Arena
Sarepta pushes for full approval of Duchenne drugs despite missed confirmatory trial goal
Nov 4, 2025 • Fierce Pharma
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
Nov 4, 2025 • BioSpace
Sarepta shares tumble on trial failure, weak Elevidys outlook
Nov 4, 2025 • Reuters
Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 (NASDAQ:SRPT)
Nov 4, 2025 • Seeking Alpha
Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook
Nov 4, 2025 • Investor's Business Daily
Sarepta Therapeutics’ dismal quarter marred by drug failures and a long list of excuses
Nov 4, 2025 • statnews.com
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Nov 3, 2025 • Sarepta Therapeutics
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates
Nov 3, 2025 • Yahoo Finance
Sarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal
Nov 3, 2025 • Reuters
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Oct 27, 2025 • Business Wire
Is Sarepta Therapeutics a Bargain After Its Wild 22% Surge and 82% Yearly Drop?
Oct 24, 2025 • Yahoo Finance
Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial
Oct 20, 2025 • CGTLive®
Sarepta’s Not Done With Gene Therapy Yet as LGMD Asset Yields Promising Data
Oct 15, 2025 • BioSpace
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline
Oct 10, 2025 • Seeking Alpha
Sarepta to seek approval for gene therapy in rare form of muscular dystrophy
Oct 10, 2025 • statnews.com
Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug
Oct 8, 2025 • statnews.com
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
Oct 8, 2025 • Stocktwits
A Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price Gains
Oct 6, 2025 • Yahoo Finance
Sarepta Therapeutics (SRPT) Is Up 23.3% After FDA Lifts Elevidys Hold and Advances SRP-1003 Trial – Has The Bull Case Changed?
Oct 5, 2025 • simplywall.st
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
Oct 3, 2025 • Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 30, 2025 • Business Wire
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles
Sep 22, 2025 • Investing.com
STAT+: Critics call on Sarepta to show how it’s measuring gene therapy’s performance
Sep 16, 2025 • STAT
Doctors Still Prescribing Sarepta’s DMD Gene Therapy After Safety Concerns
Sep 16, 2025 • BioSpace
MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
Sep 16, 2025 • BioSpace
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Sep 15, 2025 • PR Newswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Sep 15, 2025 • Canada NewsWire
Capsida Reports Patient Death in Gene Therapy Trial
Sep 11, 2025 • BioSpace
Marquis Who's Who Honors Alex Lagadinos for Expertise in Biotechnology Business Development
Sep 9, 2025 • 24-7 Press Release Newswire
Sarepta price target raised by $3 at Leerink, here's why
Sep 9, 2025 • thefly.com
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
Sep 5, 2025 • Yahoo Finance
Chugai implements safety measures for Elevidys
Sep 5, 2025 • Pharma Letter
Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm
Sep 5, 2025 • Newsfile
Opinion: DMD Gene Therapy’s Inflection Point and the Case for Small Molecules
Sep 4, 2025 • BioSpace
Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results
Sep 3, 2025 • Yahoo Finance
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from S&P 400 - Biotechnology
Sep 2, 2025 • MarketScreener
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 600
Sep 2, 2025 • MarketScreener
Sarepta to replace Brookline Bancorp in S&P 600 at open on 9/2
Sep 2, 2025 • thefly.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from S&P 400 Health Care
Sep 2, 2025 • MarketScreener
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 600 Health Care
Sep 2, 2025 • MarketScreener
Elanco to replace Sarepta in S&P 400 at open on 9/2
Sep 2, 2025 • thefly.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from S&P 400
Sep 2, 2025 • MarketScreener
Sarepta Therapeutics Restructures Amid ELEVIDYS Challenges
Sep 1, 2025 • TipRanks
Elanco Animal Health to Replace Sarepta Therapeutics in S&P MidCap 400
Aug 27, 2025 • MarketScreener
Massachusetts R&D, Biomanufacturing Jobs Fell in ’24: Report
Aug 27, 2025 • BioSpace
Sarepta down 10% on new adverse event report, says Deutsche Bank
Aug 27, 2025 • thefly.com
Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns
Aug 25, 2025 • Yahoo Finance
Mizuho maintains Sarepta Therapeutics stock rating, lowers Elevidys sales forecast
Aug 24, 2025 • Investing.com
Sarepta Therapeutics: A Strong Opportunity Amidst The Panic (NASDAQ:SRPT)
Aug 22, 2025 • Seeking Alpha
SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline
Aug 22, 2025 • Hagens Berman Sobol Shapiro LLP
SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
Aug 22, 2025 • Morningstar.com
SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
Aug 22, 2025 • PR Newswire
SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
Aug 22, 2025 • MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
Aug 22, 2025 • Morningstar.com
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
Aug 21, 2025 • Yahoo Finance
Sarepta extends $700M debt to 2030, adds private placement amid Elevidys uncertainty
Aug 21, 2025 • Fierce Pharma
As Sarepta Therapeutics fights for Duchenne therapy, a group of patients gets left behind
Aug 21, 2025 • statnews.com
Sarepta debt refinancing eases liquidity concerns, says Barclays
Aug 21, 2025 • thefly.com
Sarepta Therapeutics stock falls after refinancing convertible notes
Aug 21, 2025 • Investing.com
Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
Aug 21, 2025 • MarketScreener
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Aug 21, 2025 • Newsfile
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
Aug 21, 2025 • PR Newswire
STAT+: As Sarepta Therapeutics fights for Duchenne therapy, a group of patients gets left behind
Aug 21, 2025 • STAT
INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT
Aug 21, 2025 • PR Newswire
Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT
Aug 21, 2025 • The Gross Law Firm
Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT
Aug 21, 2025 • Morningstar.com
Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling"
Aug 20, 2025 • Yahoo Finance
How the Roche Shipment News Impacts Sarepta Therapeutics Valuation in 2025
Aug 20, 2025 • simplywall.st
SRPT 6-DAY DEADLINE ALERT: Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman
Aug 19, 2025 • Newsfile
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT
Aug 19, 2025 • Levi & Korsinsky, LLP
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders
Aug 18, 2025 • GlobeNewswire
Sarepta shares more Elevidys safety data in response to patient group's FDA petition
Aug 18, 2025 • Fierce Pharma
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman
Aug 18, 2025 • Hagens Berman Sobol Shapiro LLP
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Aug 18, 2025 • Bernstein Liebhard LLP
The week in pharma: action, reaction and insight – week to August 15
Aug 17, 2025 • Pharma Letter
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Aug 15, 2025 • Bronstein, Gewirtz & Grossman, LLC
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Aug 15, 2025 • Business Wire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Aug 15, 2025 • Newsfile
Sarepta Therapeutics Still Faces Elevidys Demand Uncertainty, Deutsche Bank Says
Aug 15, 2025 • MarketScreener
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law before Imminent August 25 Deadline (NASDAQ:SRPT)
Aug 15, 2025 • Bleichmar Fonti & Auld
Sarepta sells stake in Arrowhead amidst cash crunch
Aug 14, 2025 • FirstWord Pharma
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Aug 14, 2025 • Yahoo Finance
Sarepta offloads Arrowhead stake to fund milestone payment
Aug 14, 2025 • Pharma Letter
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
Aug 14, 2025 • MarketScreener
Sarepta sells $174M in Arrowhead stock to stretch cash runway
Aug 13, 2025 • Fierce Biotech
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
Aug 13, 2025 • BioSpace
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
Aug 13, 2025 • BioSpace
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Aug 13, 2025 • BioSpace
SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline
Aug 13, 2025 • Bleichmar Fonti & Auld
Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths
Aug 13, 2025 • BioSpace

Links

www.sarepta.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.